{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:33:49Z","timestamp":1791304429815,"version":"4.3.1"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T00:00:00Z","timestamp":1534896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R44HD075636"],"award-info":[{"award-number":["R44HD075636"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI113048"],"award-info":[{"award-number":["U19AI113048"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001439"],"award-info":[{"award-number":["UL1 TR001439"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001079"],"award-info":[{"award-number":["UL1 TR001079"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Johns Hopkins Center for AIDS Research","award":["P30AI094189"],"award-info":[{"award-number":["P30AI094189"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0201952","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T17:33:58Z","timestamp":1534959238000},"page":"e0201952","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3051-9551","authenticated-orcid":true,"given":"Kathleen Listiak","family":"Vincent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1670-8786","authenticated-orcid":true,"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5696-8665","authenticated-orcid":true,"given":"Craig W.","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4677-6782","authenticated-orcid":true,"given":"Peter A.","family":"Anton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjula","family":"Gunawardana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren N.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevelyn J.","family":"Olive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2215-5500","authenticated-orcid":true,"given":"Richard B.","family":"Pyles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1558-5649","authenticated-orcid":true,"given":"Marc M.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,8,22]]},"reference":[{"key":"ref1","first-page":"221","article-title":"Drug Delivery and Development of Anti-HIV Microbicides","author":"JA Moss","year":"2014"},{"issue":"9","key":"ref2","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1128\/AAC.02871-14","article-title":"Pharmacokinetics and Preliminary Safety Study of Pod-Intravaginal Rings Delivering Antiretroviral Combinations for HIV Prophylaxis in a Macaque Model","volume":"58","author":"JA Moss","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1128\/AAC.00391-16","article-title":"Combination Pod-intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model","volume":"60","author":"JA Moss","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"ref4","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s10461-012-0248-4","article-title":"Vaginal Ring Adherence in Sub-Saharan Africa: Expulsion, Removal, and Perfect Use","volume":"16","author":"ET Montgomery","year":"2012","journal-title":"AIDS Behav"},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1002\/jps.23208","article-title":"An Intravaginal Ring for the Simultaneous Delivery of Multiple Drugs","volume":"101","author":"MM Baum","year":"2012","journal-title":"J Pharm Sci"},{"issue":"6","key":"ref6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/QAD.0b013e3283509abb","article-title":"Tenofovir and Tenofovir Disoproxil Pharmacokinetics from Intravaginal Rings","volume":"26","author":"JA Moss","year":"2012","journal-title":"Aids"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1128\/AAC.01198-12","article-title":"Safety and Pharmacokinetics of Intravaginal Rings Delivering Tenofovir in Pig-tailed Macaques","volume":"56","author":"JA Moss","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1128\/AAC.05662-11","article-title":"Simultaneous Delivery of Tenofovir and Acyclovir via an Intravaginal Ring","volume":"56","author":"JA Moss","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref9","article-title":"Phase I Trial of Pod-intravaginal Rings Delivering Antiretroviral Agents for HIV-1 Prevention: Safety and Pharmacokinetics of Single (TDF), Dual (TDF-FTC), and Triple (TDF-FTC-MVC) Drug Formulations","author":"KL Vincent","year":"2018","journal-title":"PLoS Med"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1128\/AAC.00597-11","article-title":"The Pharmacokinetics of Tenofovir Following Intravaginal and Intrarectal Administration of Tenofovir Gel to Rhesus Macaques","volume":"56","author":"J Nuttall","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"e55013","DOI":"10.1371\/journal.pone.0055013","article-title":"MTN-001: Randomized Pharmacokinetic Cross-over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments","volume":"8","author":"CW Hendrix","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"ref12","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1128\/AAC.04954-14","article-title":"The Sheep as a Model of Preclinical Safety and Pharmacokinetic Evaluations of Candidate Microbicides","volume":"59","author":"JD Holt","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref13","unstructured":"Nair G, Justman JE, Piper J, Marzinke M, Hendrix C, Dai J, et al., editors. Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: a Cross-compartmental Study with Directly Observed Dosing. 8th IAS Conference on Pathogenesis Treatment &amp; Prevention; 2015 July 21; Vancouver, Canada."},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/QAD.0000000000000979","article-title":"A Phase 1 Randomized Placebo-controlled Safety and Pharmacokinetic Trial of a Tenofovir Disoproxil Fumarate Vaginal Ring","volume":"30","author":"MJ Keller","year":"2016","journal-title":"Aids"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/OLQ.0b013e3181cbf77d","article-title":"Prevalence and Correlates of Heterosexual Anal Intercourse Among Clients Attending Public Sexually Transmitted Disease Clinics in Los Angeles County","volume":"37","author":"M Javanbakht","year":"2010","journal-title":"Sex Transm Dis"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/QAI.0000000000000314","article-title":"Order of Orifices: Sequence of Condom Use and Ejaculation by Orifice During Anal Intercourse Among Women: Implications for HIV Transmission","volume":"67","author":"PM Gorbach","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"ref17","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1007\/s10461-015-0997-y","article-title":"Prevalence and Frequency of Heterosexual Anal Intercourse Among Young People: A Systematic Review and Meta-analysis","volume":"19","author":"BN Owen","year":"2015","journal-title":"AIDS Behav"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1089\/aid.2012.0262","article-title":"RMP-02\/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Tenofovir 1% Gel Compared with Oral Tenofovir Disoproxil Fumarate","volume":"28","author":"PA Anton","year":"2012","journal-title":"AIDS Res Hum Retrovir"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1089\/aid.2012.0073","article-title":"Dose-response Relationship Between Tissue Concentrations of UC781 and Explant Infectibility with HIV Type 1 in the RMP-01 Rectal Safety Study","volume":"28","author":"N Richardson-Harman","year":"2012","journal-title":"AIDS Res Hum Retrovir"},{"key":"ref20","first-page":"S146","article-title":"Population PK Model of Rectal 1% Tenofovir (TFV) Gel in the Rectum and Plasma","volume":"40","author":"KH Yang","year":"2013","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"e0125363","DOI":"10.1371\/journal.pone.0125363","article-title":"A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study)","volume":"10","author":"I McGowan","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/QAI.0000000000000897","article-title":"A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film","volume":"71","author":"KE Bunge","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"28","key":"ref23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004174","article-title":"Pharmacodynamic Correlations Using Fresh and Cryopreserved Tissue Following Use of Vaginal Rings Containing Dapivirine and\/or Maraviroc in a Randomized, Placebo Controlled Trial","volume":"95","author":"CS Dezzutti","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"E569","DOI":"10.1016\/S2352-3018(16)30113-8","article-title":"Long-acting Rilpivirine as Potential Pre-exposure Prophylaxis for HIV-1 Prevention (the MWRI-01 study): an Open-label, Phase 1, Compartmental, Pharmacokinetic and Pharmacodynamic Assessment","volume":"3","author":"I McGowan","year":"2016","journal-title":"Lancet HIV"},{"key":"ref25","article-title":"Analytical Advances in the <italic>Ex Vivo<\/italic> Challenge Efficacy Assay","author":"N Richardson-Harman","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1089\/aid.2016.0040","article-title":"Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B)","volume":"33","author":"JA Robinson","year":"2017","journal-title":"AIDS Res Hum Retrovir"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijpharm.2015.09.028","article-title":"An Intravaginal Ring for the Sustained Delivery of Tenofovir Disoproxil Fumarate","volume":"495","author":"MM Baum","year":"2015","journal-title":"Int J Pharm"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jpba.2014.06.018","article-title":"Dual Quantification of Dapivirine and Maraviroc in Cervicovaginal Secretions from Ophthalmic Tear Strips and Polyester-based Swabs via Liquid Chromatographic-tandem Mass Spectrometric (LC-MS\/MS) Analysis","volume":"98","author":"TL Parsons","year":"2014","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/aid.2015.0182","article-title":"Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)","volume":"32","author":"CW Hendrix","year":"2016","journal-title":"AIDS Res Hum Retrovir"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jpba.2016.08.016","article-title":"Development and Validation of a Liquid Chromatographic-tandem Mass Spectrometric Method for the Multiplexed Quantification of Etravirine, Maraviroc, Raltegravir, and Rilpivirine in Human Plasma and Tissue","volume":"131","author":"TL Parsons","year":"2016","journal-title":"J Pharm Biomed Anal"},{"key":"ref31","unstructured":"US FDA. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), 2001 May. Report No."},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/AAC.42.3.612","article-title":"Anti-human Immunodeficiency Virus Activity and Cellular Metabolism of a Potential Prodrug of the Acyclic Nucleoside Phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA","volume":"42","author":"BL Robbins","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"ref33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/095632029700800610","article-title":"Synthesis, in Vitro Biological Evaluation and Oral Bioavailability of 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) Prodrugs","volume":"8","author":"MN Arimilli","year":"1997","journal-title":"Antivir Chem Chemother"},{"key":"ref34","unstructured":"TRUVADA (Emtricitabine and Tenofovir Disoproxil Fumarate) Silver Spring, MD: U.S. Food and Drug Administration; [cited 2014 Oct. 14]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021752s043lbl.pdf\" xlink:type=\"simple\">http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021752s043lbl.pdf<\/ext-link>."},{"issue":"11","key":"ref35","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/aid.2004.20.1173","article-title":"Pharmacokinetic and Pharmacodynamic Characteristics of Emtricitabine Support Its Once Daily Dosing for the Treatment of HIV Infection","volume":"20","author":"LH Wang","year":"2004","journal-title":"AIDS Res Hum Retrovir"},{"issue":"7","key":"ref36","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose-response Curve Slope Sets Class-specific Limits on Inhibitory Potential of Anti-HIV Drugs","volume":"14","author":"L Shen","year":"2008","journal-title":"Nature Med"},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.2649","article-title":"A Quantitative Basis for Antiretroviral Therapy for HIV-1","volume":"18","author":"BL Jilek","year":"2012","journal-title":"Infection. Nat Med"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"e1003982","DOI":"10.1371\/journal.ppat.1003982","article-title":"Highly Active Antiretroviral Therapies Are Effective against HIV-1 Cell-to-Cell Transmission","volume":"10","author":"LM Agosto","year":"2014","journal-title":"PLoS Pathog"},{"issue":"11","key":"ref39","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"a Potent, Orally Bioavailable, and Selective Small-molecule Inhibitor of Chemokine Receptor CCR5 with Broad-spectrum Anti-human Immunodeficiency Virus Type 1 Activity","volume":"49","author":"P Dorr","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tips.2009.10.001","article-title":"The Complexities of Antiretroviral Drug-drug Interactions: Role of ABC and SLC Transporters","volume":"31","author":"O Kis","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"ref41","article-title":"Frontiers in Clinical Drug Research","author":"RB Pyles","year":"2015"},{"issue":"5","key":"ref42","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/aid.2016.0167","article-title":"A Comparative Pre-Phase I Study of the Impact of Gel Vehicle Volume on Distal Colon Distribution, User Experience, and Acceptability","volume":"33","author":"ED Weld","year":"2017","journal-title":"AIDS Res Hum Retrovir"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0201952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:45:21Z","timestamp":1661820321000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0201952"}},"subtitle":[],"editor":[{"given":"Timothy R.","family":"Cressey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,8,22]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0201952","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,22]]}}}